Changeflow GovPing Pharma & Drug Safety FDA Class II Drug Recall: Agebox iKids-Growth C...
Urgent Enforcement Removed Final

FDA Class II Drug Recall: Agebox iKids-Growth Capsules

Favicon for changeflow.com FDA: Drug Recalls Class II
Filed March 4th, 2026
Detected March 28th, 2026
Email

Summary

The FDA has initiated a Class II recall for Agebox iKids-Growth (Day Formula) capsules due to the presence of undeclared ibutamoren. The product was distributed nationwide in the U.S. through Agebox.com and Amazon.com.

What changed

The Food and Drug Administration (FDA) has issued a Class II recall for Agebox iKids-Growth (Day Formula) capsules (60-count bottles, UPC 8 50065 59701 0). The recall is due to the product being marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), specifically because it contains undeclared ibutamoren. The product was manufactured exclusively for AGEBOX Inc. and distributed nationwide via Agebox.com and Amazon.com.

This action requires Agebox Inc. and its distributors to immediately cease distribution and notify retailers and consumers about the recall. While classified as Class II, indicating that use or exposure may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote, affected parties should take prompt action to remove the product from shelves and inform consumers. The FDA is monitoring the recall process, which is ongoing.

What to do next

  1. Remove Agebox iKids-Growth capsules from inventory and distribution channels.
  2. Notify all retailers and consumers about the recall and the presence of undeclared ibutamoren.
  3. Comply with FDA reporting requirements for the recall process.

Source document (simplified)

Agebox

Drug Recalls (Class II)

← All Drug Recalls (Class II) Class II D-0344-2026 · 20260304 · Ongoing

Product

Agebox iKids-Growth (Day Formula) capsules, 60-count bottles, Manufactured Exclusively For: AGEBOX Inc., Wilmington, DE 19801 USA, UPC 8 50065 59701 0

Reason for Recall

Marketed Without an Approved NDA/ANDA: presence of undeclared ibutamoren

Distribution

The product was distributed nationwide in the U.S. Agebox sells its U.S. products through Agebox.com (using Shopify) and Amazon.com. All orders are...

Source: openFDA Enforcement API

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
FDA
Filed
March 4th, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
D-0344-2026

Who this affects

Applies to
Drug manufacturers Consumers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Recalls
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11
Topics
Product Safety Consumer Protection

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when FDA: Drug Recalls Class II publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.